Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
A recombinant virus vector constructed from adeno-associated virus (AAV) that has been altered to carry the human alpha1-antitrypsin (hAAT) gene expressed from a hybrid chicken beta-actin promoter with a cytomegalovirus enhancer has been developed. The construct has been shown to initiate the production of hAAT in animal models closely matching the proposed human trial. The proposed clinical trial is an open-label, phase I study administering recombinant adeno-associated virus alpha1-antitrypsin (rAAV2-CB-hAAT) gene vector intramuscularly to AAT-deficient human subjects where gene expression can be measured directly in blood samples to assess safety. Safety parameters will be measurement of changes in serum chemistries and hematology, urinalysis, pulmonary function testing, semen assay for vector genomes, immunologic response to AAT, and AAV, as well as reported subject history of any symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“87,88 91 Finally, the availability of several column chromatography methods, including heparin sulfate affinity column chromatography, has allowed for the elimination of CsCl banding, which in turn appears to have enhanced the infectivity of output particles.”
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583 · cited 1×
“85,86 The full exploitation of rAAV for gene transfer has been limited in the past primarily by the packaging and purification process.”
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“92 rAAV vectors are uniquely suitable for in vivo gene therapy for genetic and metabolic disorders, since they are nontoxic 93–95 highly efficient when used at high titers, relatively nonimmunogenic, 96–98 and very stable in their pattern of expression.”
The cryptic life style of adenoassociated virus
Berns, K. I., & Linden, R. M. (1995) · BioEssays · doi:10.1002/bies.950170310 · Cited by 268
In vivo model of adeno-associated virus vector persistence and rescue
Afione, S. A., Conrad, C. K., Kearns, W. G., Chunduru, S., Adams, R., Reynolds, T. C., Guggino, W. B., Cutting, G. R., Carter, B. J., & Flotte, T. R. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3235-3241.1996 · Cited by 223 · cited 3×
“37,77 The AAV genome consists of two 145-nucleotide inverted terminal repeat (ITR) sequences, each an identical palindrome at either terminus of the virus, flanking the two AAV genes, rep and cap .”
Halbert, C. L., Standaert, T. A., Wilson, C. B., & Miller, A. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9795-9805.1998 · Cited by 203
Tratschin, J. D., West, M. H., Sandbank, T., & Carter, B. J. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.10.2072 · Cited by 202
Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells
Flotte, T. R., Solow, R., Owens, R. A., Afione, S., Zeitlin, P. L., & Carter, B. J. (1992) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb/7.3.349 · Cited by 167 · cited 1×
“85,86 The full exploitation of rAAV for gene transfer has been limited in the past primarily by the packaging and purification process.”
Self-citationRecombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle
Clark, K. R., Sferra, T. J., & Johnson, P. R. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.6-659 · Cited by 153
Research works printed but not linked: 105
- 10.1016/0168-9525(89)90200-X · DOI · Paper page
- Ogushi F., 1988, Am. Rev. Respir. Dis., 137, 364, 10.1164/ajrccm/137.2.364 · DOI
- 10.1378/chest.100.3.703 · DOI · Paper page
- Cox D.W., 1988, Am. Rev. Respir. Dis., 137, 371, 10.1164/ajrccm/137.2.371 · doi:10.1164/ajrccm/137.2.371
- 10.1172/JCI115066 · DOI
- Casolaro M.A., 1987, J. Appl. Physiol., 63, 2015, 10.1152/jappl.1987.63.5.2015 · DOI
- 10.1378/chest.110.1.78 · DOI
- 10.1056/NEJM198704233161704 · DOI · Paper page
- Wewers M.D., 1987, Am. Rev. Respir. Dis., 135, 539
- 10.1073/pnas.86.2.680 · doi:10.1073/pnas.86.2.680
- 10.1165/ajrcmb.10.1.8292378 · DOI · Paper page
- 10.1126/science.2017680 · DOI · Paper page
- 10.1165/ajrcmb.10.4.8136153 · DOI
- 10.1089/hum.1996.7.4-531 · DOI
- Kay M.A., 1995, Hepatology, 21, 815
- 10.1006/bbrc.1994.2565 · DOI
- 10.1016/0006-2952(96)00038-X · DOI
- 10.1111/1523-1747.ep12372181 · DOI
- 10.1089/hum.1992.3.6-641 · DOI · Paper page
- 10.1073/pnas.89.1.89 · DOI · Paper page
- Levy M.Y., 1996, Gene Ther., 3, 201
- Meyer K.B., 1995, Gene Ther., 2, 450
- Qiu P., 1996, Gene Ther., 3, 262
- Guo Z.S., 1996, Gene Ther., 3, 802
- 10.1038/ng0298-180 · DOI · Paper page
- 10.1073/pnas.95.24.14384 · DOI · Paper page
- 10.1073/pnas.90.22.10613 · DOI · Paper page
- 10.1038/ng1094-148 · DOI · Paper page
- 10.1073/pnas.94.13.6916 · DOI · Paper page
- Zolotukhin S., 1996, J. Virol., 70, 4646, 10.1128/JVI.70.7.4646-4654.1996 · DOI · Paper page
- 10.1038/sj.gt.3300358 · DOI · Paper page
- 10.1038/ng0797-270 · DOI · Paper page
- 10.1073/pnas.93.24.14082 · DOI · Paper page
- Xiao X., 1996, J. Virol., 70, 8098, 10.1128/JVI.70.11.8098-8108.1996 · DOI · Paper page
- Conrad C.K., 1996, Gene Ther., 3, 658
- 10.1038/358581a0 · DOI · Paper page
- Flotte T.R., 1993, J. Biol. Chem., 268, 3781, 10.1016/S0021-9258(18)53762-5 · DOI · Paper page
- Schwiebert E.M., 1994, Am. J. Physiol., 266, C1464, 10.1152/ajpcell.1994.266.5.C1464 · DOI
- 10.1089/hum.1996.7.9-1145 · DOI · Paper page
- 10.1097/00005537-199902000-00017 · DOI · Paper page
- 10.1016/S0140-6736(05)77740-0 · DOI · Paper page
- 10.1038/sj.gt.3301268 · DOI
- 10.1002/(SICI)1097-0061(19980315)14:4<371::AID-YEA231>3.3.CO;2-T · doi:10.1002/(sici)1097-0061(19980315)14:4<371::aid-yea231>3.3.co;2-t
- Tebbutt S.J., 2000, Curr. Opin. Mol. Ther., 2, 199
- 10.1038/sj.gt.3301541 · DOI · Paper page
- 10.1038/sj.gt.3301422 · DOI
- Carter B.J., 1975, J. Virol., 16, 559, 10.1128/JVI.16.3.559-568.1975 · DOI · Paper page
- 10.1007/978-1-4684-8730-5_15 · DOI
- 10.1016/0042-6822(66)90045-6 · DOI
- 10.1073/pnas.55.6.1467 · DOI · Paper page
- Hoggan M.D., 1968, J. Virol., 2, 850, 10.1128/JVI.2.8.850-851.1968 · DOI
- 10.1073/pnas.58.4.1410 · DOI · Paper page
- Blacklow N.R., 1968, J. Natl. Cancer Inst., 40, 319
- 10.1099/0022-1317-10-1-29 · DOI
- 10.1093/oxfordjournals.aje.a120897 · DOI · Paper page
- Flotte T.R., 1995, Gene Ther., 2, 357
- Summerford C., 1998, J. Virol., 72, 1438, 10.1128/JVI.72.2.1438-1445.1998 · DOI · Paper page
- 10.1038/8526 · DOI · Paper page
- 10.1038/4768 · DOI · Paper page
- 10.1016/0042-6822(75)90298-6 · DOI
- Cheung A.K., 1980, J. Virol., 33, 739, 10.1128/JVI.33.2.739-748.1980 · DOI · Paper page
- 10.1073/pnas.87.6.2211 · DOI · Paper page
- 10.1016/0888-7543(91)90470-Y · DOI · Paper page
- Kotin R.M., 1992, EMBO J, 11, 5071, 10.1002/j.1460-2075.1992.tb05614.x · DOI · Paper page
- Samulski R.J., 1991, EMBO J, 10, 3941, 10.1002/j.1460-2075.1991.tb04964.x · DOI · Paper page
- 10.1016/S0959-437X(05)80344-2 · DOI · Paper page
- 10.1073/pnas.91.13.5808 · DOI · Paper page
- 10.1073/pnas.91.21.10039 · DOI · Paper page
- Giraud C., 1995, J. Virol., 69, 6917, 10.1128/JVI.69.11.6917-6924.1995 · DOI · Paper page
- 10.1073/pnas.93.21.11288 · DOI · Paper page
- Kearns W.G., 1996, Gene Ther., 3, 748
- 10.1165/ajrcmb.11.5.7946381 · DOI · Paper page
- 10.1016/0022-2836(84)90303-6 · DOI
- 10.1016/0092-8674(90)90526-K · DOI · Paper page
- Pereira D.J., 1997, J. Virol., 71, 1747, 10.1128/JVI.71.3.1747-1756.1997 · DOI · Paper page
- Pereira D.J., 1997, J. Virol., 71, 1079, 10.1128/JVI.71.2.1079-1088.1997 · DOI · Paper page
- Trempe J.P., 1988, J. Virol., 62, 3356, 10.1128/JVI.62.9.3356-3363.1988 · DOI · Paper page
- 10.1128/JVI.74.18.8635-8647.2000 · DOI · Paper page
- 10.1089/10430349950018715 · DOI · Paper page
- Li J., 1997, J. Virol., 71, 5236, 10.1128/JVI.71.7.5236-5243.1997 · DOI · Paper page
- Clark K.R., 1996, Gene Ther., 3, 1124
- Flotte T.R., 1995, Gene Ther., 2, 29
- 10.1089/hum.1998.9.16-2353 · DOI · Paper page
- 10.1038/sj.gt.3300938 · DOI · Paper page
- 10.1073/pnas.90.22.10613 · DOI · Paper page
- Conrad C.K., 1996, Gene Ther., 3, 658
- 10.1016/S0076-6879(98)92055-9 · DOI
- Beck S.E., 1999, J. Virol., 73, 9446, 10.1128/JVI.73.11.9446-9455.1999 · DOI · Paper page
- Hernandez Y.J., 1999, J. Virol., 73, 8549, 10.1128/JVI.73.10.8549-8558.1999 · DOI · Paper page
- 10.1038/ng1094-148 · DOI · Paper page
- 10.1016/0006-8993(95)01488-8 · DOI · Paper page
- Tebbutt S.J., 2000, Curr. Opin. Mol. Ther., 2, 199
- 10.1073/pnas.94.25.14083 · DOI · Paper page
- Xiao X., 1996, J. Virol., 70, 8098, 10.1128/JVI.70.11.8098-8108.1996 · DOI · Paper page
- 10.1073/pnas.93.24.14082 · DOI · Paper page
- 10.1038/nm0397-306 · DOI · Paper page
- 10.1073/pnas.95.24.14384 · DOI · Paper page
- 10.1073/pnas.94.13.6916 · DOI · Paper page
- Lewin A.S., 1998, Med., 4, 967
- Zolotukhin S., 1996, J. Virol., 70, 4646, 10.1128/JVI.70.7.4646-4654.1996 · DOI · Paper page
- 10.1089/10430349950018715 · DOI · Paper page
- 10.1073/pnas.061014598 · DOI · Paper page
- Tratschin J.D., 1984, J. Virol., 51, 611, 10.1128/JVI.51.3.611-619.1984 · DOI · Paper page
- Summerford C., 1998, J. Virol., 72, 1438, 10.1128/JVI.72.2.1438-1445.1998 · DOI · Paper page
- 10.1006/mthe.2002.0673 · DOI · Paper page
Cited by
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Stoller, J. K., & Aboussouan, L. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66781-5 · Cited by 695
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Stable antibody expression at therapeutic levels using the 2A peptide
Fang, J., Qian, J.-J., Yi, S., Harding, T. C., Tu, G. H., VanRoey, M., & Jooss, K. (2005) · Nature Biotechnology · doi:10.1038/nbt1087 · Cited by 370
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Self-citation
Metadata
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 15
- Issue
- 1
- Pages
- 93-128
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W23651898
- Cited by
- 146
- References
- 10
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. https://app.cochat.ai/papers/10.1089/10430340460732490
- The paper
- Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. (2004). Human Gene Therapy. https://doi.org/10.1089/10430340460732490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.